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Cellular/Molecular

Matrix Metalloproteinase-Mediated Blood-Brain Barrier
Dysfunction in Epilepsy
Ralf G. Rempe,1 Anika M.S. Hartz,2,3 Emma L.B. Soldner,4 X Brent S. Sokola,1 X Satya R. Alluri,1 Erin L. Abner,2
Richard J. Kryscio,2,5 X Anton Pekcec,4 Juli Schlichtiger,4 and X Björn Bauer1,6
1

Department of Pharmaceutical Sciences, College of Pharmacy, 2Sanders-Brown Center on Aging, 3Department of Pharmacology and Nutritional Sciences,
Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota, Duluth, Minnesota 55812, 5Department of
Statistics, and 6Epilepsy Center, University of Kentucky, Lexington, Kentucky 40536
4

The blood-brain barrier is dysfunctional in epilepsy, thereby contributing to seizure genesis and resistance to antiseizure drugs. Previously, several groups reported that seizures increase brain glutamate levels, which leads to barrier dysfunction. One critical component
of barrier dysfunction is brain capillary leakage. Based on our preliminary data, we hypothesized that glutamate released during seizures
mediates an increase in matrix-metalloproteinase (MMP) expression and activity levels, thereby contributing to barrier leakage. To test
this hypothesis, we exposed isolated brain capillaries from male Sprague Dawley rats to glutamate ex vivo and used an in vivo/ex vivo
approach of isolated brain capillaries from female Wistar rats that experienced status epilepticus as an acute seizure model. We found
that exposing isolated rat brain capillaries to glutamate increased MMP-2 and MMP-9 protein and activity levels, and decreased tight
junction protein levels, which resulted in barrier leakage. We confirmed these findings in vivo in rats after status epilepticus and in brain
capillaries from male mice lacking cytosolic phospholipase A2. Together, our data support the hypothesis that glutamate released during
seizures signals an increase in MMP-2 and MMP-9 protein expression and activity levels, resulting in blood-brain barrier leakage.
Key words: barrier dysfunction; barrier leakage; Blood-Brain barrier; cPLA2 ; MMP

Significance Statement
The mechanism leading to seizure-mediated blood-brain barrier dysfunction in epilepsy is poorly understood. In the present
study, we focused on defining this mechanism in the brain capillary endothelium. We demonstrate that seizures trigger a pathway
that involves glutamate signaling through cytosolic phospholipase A2 , which increases MMP levels and decreases tight junction
protein expression levels, resulting in barrier leakage. These findings may provide potential therapeutic avenues within the
blood-brain barrier to limit barrier dysfunction in epilepsy and decrease seizure burden.

Introduction
With ⬎70 million patients worldwide, epilepsy is one of the most
common neurological disorders (Ngugi et al., 2010; World Health
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Organization, 2017). Approximately one-third of epilepsy patients suffer from refractory epilepsy and do not respond well to
treatment with antiseizure drugs (ASDs) (Kwan and Brodie,
2010). These patients experience uncontrolled seizures and comorbidities that severely impact their quality of life (Edefonti et
al., 2011; Tang et al., 2017).
Recent findings suggest that epilepsy etiology and pathology
are not solely based on neuronal dysfunction. Altered immune
response, glial dysfunction, persistent brain inflammation, and a
dysfunctional blood-brain barrier also appear to play a role in epilepsy pathophysiology (Vezzani and Granata, 2005; Coulter and Eid,
2012; Heinemann et al., 2012; Sada et al., 2015). In the present
study, we focus on barrier leakage, which is a key component of
barrier dysfunction. Recently, several groups have shown that
barrier leakage plays a role in epilepsy progression (Marchi et al.,
2007b, 2010; Rigau et al., 2007; van Vliet et al., 2007; Tomkins et
al., 2008; Kastanauskaite et al., 2009; Alonso-Nanclares and DeFelipe, 2014). For example, Marchi et al. (2009) and Salar et al.
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(2014) showed that barrier leakage potentially contributes to
ASD resistance in refractory epilepsy. One explanation these authors provide is that serum proteins such as albumin enter the
brain through a leaky barrier, then upon extravasation bind ASDs
in the brain parenchyma, lowering brain concentration of free,
unbound ASD, thereby limiting ASD brain levels and reducing
ASD efficacy (Marchi et al., 2009; Salar et al., 2014). Moreover,
multiple groups have demonstrated that barrier leakage is both a
consequence and a trigger of seizures (Seiffert et al., 2004; Fabene
et al., 2008; Marchi et al., 2011). This implies that a leaky barrier
contributes to seizure genesis through a positive feedback loop, in
which seizures drive barrier leakage leading to more seizures, thereby
promoting epilepsy progression. Thus, strategies to repair barrier
dysfunction could be valuable add-on treatments to existing
pharmacotherapy. However, the mechanism of seizure-induced
barrier leakage is not fully understood, and strategies to repair a
leaky barrier are not available.
The data we present here suggest that seizures increase matrix
metalloproteinase (MMP) expression and activity levels in capillary endothelial cells of the blood-brain barrier. In the neurovasculature, MMPs likely affect barrier integrity by digesting and
remodeling the extracellular matrix surrounding brain capillaries
and by degrading tight junction proteins that seal the endothelium (Lischper et al., 2010; Feng et al., 2011). Based on our data
and reports from others, we postulated that seizures cause MMP
upregulation at the blood-brain barrier that leads to degradation
of tight junctions and results in barrier leakage.
We used pilocarpine to induce status epilepticus (SE) in rats
and then isolated brain capillaries from these animals after acute
SE. We found increased MMP-2 and MMP-9 activity levels, decreased tight junction expression levels, and barrier leakage in
capillaries from rats after SE. Exposing rat brain capillaries to
glutamate increased MMP-2 and MMP-9 protein and activity
levels, decreased tight junction protein levels, and resulted in
barrier leakage; blocking cytosolic phospholipase A2 (cPLA2) reversed these effects. We confirmed our findings using brain capillaries from cPLA2 knock-out (KO) mice and by conducting in
vivo experiments in a rat seizure model using a cPLA2 inhibitor.
Together, our study suggests that glutamate released during
seizures increases MMP-2 and MMP-9 levels at the blood-brain
barrier, which results in reduced levels of tight junction proteins
and consequently barrier leakage. Our data imply that cPLA2
could be a target to repair barrier dysfunction and improve the
treatment of epilepsy and potentially other neurological disorders that are accompanied by blood-brain barrier leakage as well.

Materials and Methods
Chemicals and supplies. Dulbecco’s PBS (DPBS) was purchased from Fisher
Scientific. Antibody against occludin (71–1500; RRID:AB_2533977) was
obtained from Zymed Laboratories, antibody against claudin-5 (35-2500,
RRID:AB_2533200) was from Invitrogen, antibodies against MMP-2
(ab37150; RRID:AB_881512), MMP-9 (ab7299; RRID:AB_305831), ZO-1
(ab96587; RRID:AB_10680012), claudin-1 (ab56417, RRID:AB_941048),
and ␤-actin (ab8226, RRID:AB_306371), as well as MMP-9 protein were
purchased from Abcam. Rat and mouse MMP-2, rat MMP-9, and fluorogenic MMP substrate Mca-PLGL-Dpa-AR-NH2 were from R&D Systems.
GM6001 was purchased from Tocris Bioscience. The cPLA2-inhibitor
arachidonyl trifluoromethyl ketone (ATK) was from Cayman Chemical.
L-Glutamate, D-mannitol, pilocarpine, Texas Red, and all other chemicals
and reagents were purchased from Sigma-Aldrich. The Phire Tissue Direct
PCR Master Mix Kit and all other chemicals and supplies were purchased
from Thermo Fisher Scientific.
Experimental design and statistical analysis. Sample sizes (e.g., animal
numbers, number of brain capillaries to be analyzed) for individual ex-
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periments were based on power analyses of preliminary data and previously published data (Bauer et al., 2008; Pekcec et al., 2009; Zibell et al.,
2009; Hartz et al., 2017) and are given in the figure legends.
Number of repetitions are stated in Results and the figure legends.
Female Wistar rats (RGD_2312511) were used for in vivo SE inductions.
For ex vivo experiments using isolated brain capillaries, male CD IGS
Sprague Dawley rats (RGD_734476) were used. For Texas Red leakage
experiments, capillaries were isolated from male cPLA2 wild-type and
KO mice (Bonventre et al., 1997).
Statistical analyses focused on comparisons between experimental
groups and did not include adjustment variables. Two-group experiments were analyzed with two-tailed unpaired Student’s t test, whereas
ANOVA was used for more than two groups. Results presented are mean ⫾
SEM. Analyses were performed using Microsoft Excel and Prism (version
7.00, GraphPad; RRID:SCR_002798). Because animals in each experiment were independent, observed differences were considered to be
statistically significant when p ⬍ 0.05 (i.e., there were no multiple comparisons based on data from the same animals). The Anderson-Darling
test for normality was performed to confirm normal distribution of the
data. For the statistical analysis of Western blotting data presented in
Tables 1– 6, the mean for each treatment was compared with control
using Dunnett’s many-to-one t test with statistical significance determined at the 0.05 level for each endpoint.
Animals. Animal protocols were approved by the University of Minnesota and University of Kentucky Institutional Animal Care and Use
Committees (University of Minnesota Institutional Animal Care and
Use Committee #1012A93932, principal investigator B.B.; University of
Kentucky Institutional Animal Care and Use Committee #2014-1234,
principal investigator B.B.) and were in accordance with Association for
Assessment and Accreditation of Laboratory Animal Care regulations,
the Department of Agriculture Animal Welfare Act, and National Institutes of Health animal guidelines. Rats: Male CD IGS Sprague Dawley
rats (275-300 g; RGD_734476) and female Wistar rats (180-215 g;
RGD_2312511) were from Charles River Laboratories. Rats were housed
under controlled conditions (23°C, 35% relative humidity, 12 h dark/
light cycle) with free access to tap water and standard rodent feed (Harlan
Teklad Chow 2918; Harlan Laboratories). Upon arrival in the animal
facility, rats were given at least 1 week to acclimate to the new environment before experiments. Mice: Heterozygous cPLA2 breeding pairs were
a kind gift from Dr. Joseph V. Bonventre (Brigham and Women’s Hospital/Harvard Medical School) (Bonventre et al., 1997).
Genotyping of cPLA2 KO mice. Genotyping was performed for cPLA2
wild-type, heterozygous, and KO mice using ear punch samples. DNA
was isolated using the Phire Tissue Direct PCR Master Mix kit (F170S,
Thermo Fisher Scientific) according to the manufacturer’s protocol. The
2-mm-diameter ear punch samples were placed in a PCR tube containing
20 l dilution buffer and 0.4 l DNA release additive per sample. Samples were centrifuged, incubated at room temperature for 5 min, and
incubated at 98°C for 2 min using a SimpliAmp thermal cycler (Thermo
Fisher Scientific). Isolated DNA was stored at ⫺20°C until use.
The PCR was performed using the Phire Tissue Direct PCR Master
Mix (2⫻) with 3 specific primers: CGA CTC ATA CAG TGC CTT CAT
CAC (CPLA604), GGG AAC TTC CTG ACT AGG GG (PGKNEO), TGT
GTA CAA TCT TTG TGT TGT TTC A (CPLA 3F) at a final concentration of 10 M with 2.5 l of isolated DNA. The PCR was performed in a
SimpliAmp thermal cycler (Thermo Fisher Scientific); PCR conditions
were set to an initial denaturation at 98°C for 5 min; 40 cycles of a
three-step amplification, including 98°C denaturation for 5 s, 62°C annealing for 5 s, and 72°C extension for 20 s; and a final extension at 72°C
for 1 min. PCR products were resolved on E-Gel EX 4% agarose gels
using an E-Gel Precast Agarose Electrophoresis System (Thermo Fisher
Scientific). Gels were imaged using a ChemiDoc XRS⫹ System with
accompanying Image Laboratory version 5.0 software (Bio-Rad Laboratories). Expected band sizes are as follows: 100 bp for the wild-type
band and 300 bp for the cPLA2 KO band; for heterozygous mice, both
bands appeared in the agarose gel.
SE induction in rats. Female Wistar rats were handled at least 3 times
before SE induction to minimize handling stress. At 12–18 h before pilocarpine dosing, all rats were given lithium chloride (127 mg/kg) by
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intraperitoneal injection; 30 min before pilocarpine dosing, all rats were
given methylscopolamine (1 mg/kg) by intraperitoneal injection. To induce SE, rats in the pilocarpine group received pilocarpine (10 –12 mg/
kg) by repeated intraperitoneal injections every 20 –30 min until the
onset of ongoing generalized convulsive seizures. The maximum dose of
pilocarpine per animal was limited to 120 mg/kg. Behavioral seizures
were scored based on Racine’s scale (Racine, 1972), and SE was defined
by continuous tonic-clonic seizures or intermittent Class 4 and 5 seizures
without recovery of normal conscious behavior between seizures. Rats
that received pilocarpine but did not enter SE served as pilocarpine control animals. SE was continuously monitored and terminated after 90
min by intraperitoneal injections of diazepam (10 mg/kg every 20 min
until cessation of seizures). Control rats received LiCl, methylscopolamine, normal saline, and diazepam but did not receive pilocarpine.
Animals were killed 48 h after SE induction using CO2 and subsequent
decapitation.
To test the effect of cPLA2 inhibition in vivo, rats were dosed with the
selective cPLA2 inhibitor ATK (10 mg/kg, i.p.) every 12 h for 3.5 d (total
of 7 i.p. injections). After three ATK treatments, rats underwent seizure
induction with pilocarpine; after SE induction animals received 4 more
ATK treatments.
Brain capillary isolation. Brain capillaries from rat brain tissue were
isolated as previously described (Bauer et al., 2008; Hartz et al., 2017).
Rats were killed by CO2 inhalation and decapitated. The skull was opened
with bone pliers, and brains were collected in ice-cold DPBS (2.7 mM
KCl, 1.47 mM KH2PO4, 136.9 mM NaCl, 8.1 mM Na2HPO4, 0.9 mM CaCl2,
0.49 mM MgCl2, supplemented with 5 mM D-glucose and 1 mM sodium
pyruvate, pH 7.4). Brains were dissected and cleaned by removing the
brainstem, meninges, larger blood vessels, and white matter using forceps and stereomicroscopes. The remaining brain cortex tissue was
minced and homogenized in DPBS with a Potter-Elvehjem homogenizer
(clearance: 150 –230 m), followed by another homogenization using a
Dounce homogenizer (clearance: 80 –130 m). The brain homogenate
was mixed with Ficoll (final concentration 15%), and the mixture was
centrifuged at 5800 ⫻ g for 15 min at 4°C. The pellet containing brain
capillaries was resuspended in DPBS (with 1% BSA), the capillary suspension was filtered through a 300 m mesh and passed over a glass bead
column using DPBS (1% BSA). Capillaries adhering to the glass beads
were washed off and collected by agitation in DPBS (1% BSA) followed
by filtration through a 100 m cell strainer (Falcon; Corning). After
centrifugation (1500 ⫻ g, 3 min, 4°C), the capillary pellet was washed 3
times with DPBS (no BSA). Freshly isolated brain capillaries were exposed to 100 M glutamate (with/without inhibitors) for 30 min, washed,
and incubated in glutamate-free DPBS buffer for 5.5 h. After a total of 6 h,
capillaries were used for the endpoint measurements described below.
Capillary membrane isolation. Brain capillaries were lysed in CelLytic
buffer (Sigma-Aldrich) containing Complete protease inhibitor mixture
(Roche) using a Polytron 2500E homogenizer (Kinematica). The cell
lysate was first centrifuged at 10,000 ⫻ g for 30 min, and the resulting
supernatant was centrifuged at 100,000 ⫻ g for 2 h. The final pellet (crude
capillary membranes) was resuspended, and brain capillary membranes
were frozen at ⫺80°C until further use.
Western blotting. Protein concentration of brain capillary membrane
samples was determined using the Bradford protein assay. Normalized
brain capillary membrane samples were separated and transferred using
the NuPAGE electrophoresis and blotting system (Invitrogen). After
protein transfer, the blotting membranes were incubated overnight with
primary antibody (MMP-2: 1 g/ml, ab37150; RRID:AB_881512, Abcam; MMP-9: 1 g/ml, ab7299; RRID:AB_305831, Abcam; occludin: 1
g/ml, 71-1500; RRID:AB_2533977, Zymed Laboratories; claudin-1: 1
g/ml, ab56417, RRID:AB_941048, Abcam; claudin-5: 1 g/ml, 352500, RRID:AB_2533200, Invitrogen; ZO-1: 1 g/ml, ab96587; RRID:
AB_10680012, Zymed Laboratories; tissue inhibitors of metalloproteinase-1
[TIMP-1]: 1 g/ml, ab61224; RRID:AB_945838, Abcam; TIMP-2: 1 g/
ml, ab38973; RRID:AB_778471, Abcam; TIMP-3: 1 g/ml, ab39184,
RRID:AB_2204971, Abcam; or ␤-actin: 1 g/l, ab8226, RRID:AB_306371,
Abcam). After antibody incubation, the membrane was washed and incubated with the corresponding HRP-conjugated secondary antibody
(1:10,000; Pierce). Proteins were detected using SuperSignal West Pico
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chemoluminescent substrate (Pierce), and protein bands were visualized
with a Gel Doc XRS imaging system (Bio-Rad Laboratories) and analyzed
with Image Laboratory (version 5.0) software.
MMP-2 and MMP-9 ELISA. Freshly isolated brain capillaries were
lysed in CelLytic buffer (Sigma-Aldrich) containing Complete protease
inhibitor mixture using a Polytron 2500E homogenizer (Kinematica).
Samples were centrifuged at 10,000 ⫻ g for 30 min, and the resulting
supernatants were collected. To quantitate MMP-2 and MMP-9, we used
the Total MMP-2 Quantikine ELISA Kit and the Total MMP-9 Quantikine ELISA Kit according to the manufacturer’s instructions (R&D
Systems). Briefly, samples were transferred into microplates coated with
monoclonal antibody specific for MMP-2 or MMP-9, respectively, and
incubated for 2 h. Plates were washed 5 times, and HRP-linked polyclonal antibody specific for MMP-2 or MMP-9 was added for 2 h. After
another five washes, substrate solution (tetramethylbenzidine) was added
and a blue colored diimine developed proportionally to the amount of MMP
bound to antibody in the plate. After 30 min, the color reaction was
stopped by adding sulfuric acid, which turned the tetramethylbenzidine
to yellow; color intensity was measured at 450 and 570 nm (to correct for
optical imperfections in the microplate) using a Synergy H1 Hybrid
Multi-Mode Reader (BioTek). The raw data were analyzed, and results
were presented as total protein concentration in ng/ml. In preliminary
experiments, MMP-2 levels in brain capillary samples were found to be
near the detection limit (0.5 ng/ml); therefore, samples and blanks were
spiked with 4 ng/ml exogenous MMP-2 to raise levels to the linear range
of the standard curve. After detection, the values for the spiked blanks
were subtracted from the sample values to determine the actual MMP-2
concentration in the sample.
Immunohistochemistry. Brain capillaries were transferred to confocal
imaging chambers with coverslip bottoms and allowed to attach for 15
min. Capillaries were fixed for 30 min with fixation solution (3% PFA,
0.25% glutaraldehyde in PBS), permeabilized for 1 h with Surfact-Amps
X-100 (0.5% in PBS), and blocked for at least 2 h with 1% BSA (in PBS).
Brain capillaries were then incubated overnight at 4°C with MMP-2
(ab37150; RRID:AB_881512) and MMP-9 (ab7299; RRID:AB_305831)
primary antibody (concentration: 1 g/ml in 1% BSA). After washing with
1% BSA, capillaries were incubated with the corresponding AlexaFluor-488
s antibody (diluted 1:1000 in 1% BSA) for 1 h at 37°C in the dark. Subsequently, cell nuclei were counterstained for 10 min with DAPI (1 g/ml in
1% BSA). Capillaries were examined with a Zeiss LSM 710 inverted confocal microscope that was equipped with a C-Apochromat 40⫻/1.2 W
Corr objective and using the 488 nm line of an argon laser (Carl Zeiss).
Texas Red efflux assay. Texas Red efflux assays using brain capillaries
were performed as previously described (Hartz et al., 2012). Brain capillaries were transferred to glass coverslips and incubated for 1 h with
fluorescent 2 M Texas Red (sulforhodamine 101 acid chloride; 641 Da)
to load capillary lumens. After washing with DPBS, the efflux of Texas
Red from the lumen of control and treated brain capillaries was monitored with confocal microscopy. Per group, n ⫽ 7–10 brain capillary
images were taken with an LSM 710 inverted confocal microscope (CApochromat 40⫻/1.2 W Corr objective, 488 nm argon laser line; Carl
Zeiss) or a TCS SP5 confocal microscope with a 63⫻ 1.2 NA waterimmersion objective (Leica Instruments). Luminal fluorescence intensity was quantitated using Zeiss ZEN 2012 Imaging software or ImageJ
version 1.48v (Wayne Rasband, National Institutes of Health). Firstorder efflux rate constants were calculated using nonlinear regression
(Prism, version 7.00; RRID:SCR_002798, GraphPad Software).
Zymography. Isolated brain capillaries were lysed as described above,
and protein concentration of capillary lysates was determined by the
Bradford protein assay. Normalized capillary lysate samples were added
to prewashed Sepharose beads (GE Healthcare) on a spin column
(Thermo Fisher Scientific). Samples were incubated for 60 min at 4°C
while rotating at 40 rpm, followed by a 30 min incubation at room
temperature while rotating at 20 rpm. Samples were centrifuged for 2
min at 500 ⫻ g; the supernatant was discarded. The beads were washed
twice by gentle vortexing for 5 min with 500 l PBS (Ca 2⫹/Mg 2⫹/0.05%
Tween). After each washing step, the columns were centrifuged for 2 min
at 500 ⫻ g; the supernatant was discarded. MMPs adhering to the Sepharose beads were eluted by vortexing for 30 min with 40 l of a 1:1 mix
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Figure 1. Expression and activity of MMP-2 and MMP-9 in isolated brain capillaries. A, Representative immunostaining for MMP-2 (left), MMP-9 (middle), and the negative control (right; overlay
of green, blue, and transmitted light channels) in isolated rat brain capillaries. Green represents MMPs. Blue represents nuclei counterstained with DAPI. B, Western blot showing MMP-2 and MMP-9
in liver lysate, liver crude membrane fraction (MF), kidney brush border membrane (BBM), brain lysate, and choroid plexus (CP) lysate. C, Western blot showing MMP-2 and MMP-9 in brain capillary
(Cap) lysate and brain capillary crude membrane fraction (Cap MF). D, Total MMP enzyme activity in brain capillaries was measured using the fluorogenic substrate Mca-PLGL-Dpa-AR-NH2. MMP
activity was assessed in brain capillary lysate with or without MMP inhibitor (GM6001). MMP activity is given as AFU; data are mean ⫾ SEM (n ⫽ 3 independent experiments; pooled tissue from n ⫽
10 rats per experiment). **Significantly lower than control (t(2) ⫽ 10.37, p ⫽ 0.0092; unpaired t test).
of water and Novex Tris-glycine SDS sample Buffer (Invitrogen). Samples were centrifuged for 2 min at 1000 ⫻ g, and the MMP-containing
supernatants were collected. Zymography was performed with the NuPAGE electrophoresis system using Novex Zymogram Gelatin Protein
Gels (Invitrogen) according to the manufacturer’s instructions. Recombinant rat MMP-2 and MMP-9 were used as standards (R&D Systems).
Gels were first incubated for 30 min at room temperature in Novex
Zymogram Renaturing Buffer and then equilibrated for 30 min at room
temperature in Novex Zymogram Developing Buffer. After equilibration, fresh 1⫻ Novex Zymogram Developing Buffer was added and the
gel was incubated at 37°C for 36 – 40 h. The gel was stained for 8 h using

the Colloidal Blue Staining Kit (Invitrogen) according to the manufacturer’s instructions. Afterward, the gel was transferred into deionized
water for overnight destaining. The gels were imaged with a Gel Doc XRS
system (Bio-Rad Laboratories), and MMP activity was analyzed using
Image Laboratory (version 5.0) software according to a procedure described by Hu and Beeton (2010).
MMP activity measurements. Total MMP activity in isolated rat brain
capillaries was measured with a substrate activity assay using Mca-PLGLDpa-AR-NH2 fluorogenic MMP substrate (#ES001, R&D Systems).
Brain capillaries were lysed in CelLytic M (Sigma-Aldrich) using a Polytron 2500E homogenizer (Kinematica) and centrifuged at 30,000 rpm for
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Figure 2. SE increases MMP levels, decreases levels of tight junction proteins, and causes barrier leakage in brain capillaries. A, Western blot showing MMP-2, MMP-9, ZO-1, occludin, claudin-1,
and claudin-5 in isolated brain capillaries from rats after an SE induced with pilocarpine, rats that received pilocarpine but did not develop an SE (Pilo), and untreated control rats (Ctrl). ␤-Actin was
used as protein loading control. B, Western blot showing TIMP-1, TIMP-2, and TIMP-3 protein expression in isolated brain capillaries from control, pilocarpine, and SE rats. C, Representative MMP-9
gelatin zymogram of brain capillary lysates from rats after SE and from control rats. Left, Positive controls from recombinant expressed MMP-2 and MMP-9. D, Total MMP enzyme activity in brain
capillaries isolated from control rats, rats that received pilocarpine but did not develop an SE (Pilo), and rats after an SE was measured using the fluorogenic substrate Mca-PLGL-Dpa-AR-NH2. ***SE
significantly higher than control, 1.8-fold (t(2) ⫽ 78.6, p ⫽ 0.0002; ANOVA post hoc test); Pilo significantly higher than control, 1.2-fold (t(2) ⫽ 19.0, p ⫽ 0.0028; ANOVA post hoc test); n ⫽ 2
independent experiments. E, Texas Red (TR) leakage from capillaries of rats after an SE induced by pilocarpine (SE), rats that received pilocarpine but did not develop an SE (Pilo), and untreated
control rats with or without high osmotic mannitol used as positive control for barrier opening. Data are mean ⫾ SEM for n ⫽ 7 capillaries per time point from one brain capillary isolation with n ⫽
10 rats. Shown are 0 –255 AFU. First-order efflux rates were calculated using nonlinear regression. F, S100␤ levels in serum samples from control rats, rats that received pilocarpine but did not
develop an SE (Pilo), and rats after an SE was determined by ELISA. **Control versus SE: t(2) ⫽ 3.79, p ⬎ 0.0012; Pilo versus SE: t(2) ⫽ 3.58, p ⬎ 0.002 (ANOVA post hoc tests). n ⫽ 2 independent
experiments.
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30 min; the resulting supernatant was collected for MMP activity measurements. After adding 10 M Mca-PLGL-Dpa-AR-NH2, fluorescence
was measured using a Synergy H1 Hybrid Multi-Mode Reader (BioTek)
at an excitation wavelength of 320 nm and an emission wavelength of 405
nm. These settings were consistent throughout all measurements done in
this study. Blank values were subtracted from all raw values, and data
were presented as relative fluorescence (relative fluorescence units) normalized to MMP activity in control samples.
Blood serum isolation. At 48 h after SE, rats were killed by CO2 inhalation, the thoracic cavity was opened, and blood was drawn via right ventricular heart puncture. Blood was collected in a 3.5 ml SST Vacutainer (BD
Biosciences), carefully inverted 5 times, and incubated for 30 min at room
temperature. The tubes were centrifuged at 1300 ⫻ g for 10 min at 4°C in a
Marathon 3200R swing-head centrifuge (Fisher Scientific). Supernatant was
collected, aliquoted, and kept at ⫺20°C until further use.
S100␤ ELISA. The S100␤ ELISA kit (EMD Millipore, #EZHS100B33K) was used to detect S100␤ in blood serum samples. ELISA reagents,
standards, and serum samples were prepared and plated as recommended by
the manufacturer. Absorbance was measured at 450 and 590 nm using a
Synergy H1 Hybrid Multi-Mode Reader (BioTek). A standard curve was
plotted using Gen5 software (version 2.07; values at 450 nm were corrected by the absorbance at 590 nm; Four Parameter Logistic ELISA
curve fitting was chosen) to determine the concentration of S100␤ in
serum samples.

Table 1. Western blot analysis of MMP and tight junction protein expression levels
in brain capillaries isolated from rats after SE (Fig. 2A)a
Protein

Control

Pilo

SE

MMP-2
MMP-9
ZO-1
Occludin
Claudin-1
Claudin-5

100 ⫾ 5.1
100 ⫾ 5.1
100 ⫾ 13
100 ⫾ 2
100 ⫾ 5.5
100 ⫾ 3.9

95 ⫾ 6.2
93 ⫾ 5.2
83 ⫾ 11.7
108 ⫾ 2
77 ⫾ 10.9
94 ⫾ 3.5

132 ⫾ 5.2*
125 ⫾ 7.5*
29 ⫾ 3.9*
43 ⫾ 0.6*
52 ⫾ 6.6*
73 ⫾ 2.6*

Data were normalized to ␤-actin levels; values are percentage control ⫾ SD (n ⫽ 3).
*p ⬍ 0.05, each endpoint versus control (Dunnett’s many-to-one t test).

a

Table 2. Western blot analysis of TIMP protein expression levels in brain capillaries
isolated from rats after SE (Fig. 2B)a
Protein

Control

Pilo

SE

TIMP-1
TIMP-2
TIMP-3

100 ⫾ 15.8
100 ⫾ 9.8
100 ⫾ 14.3

121.2 ⫾ 17.8
107.1 ⫾ 10.9
109.7 ⫾ 15.9

235.6 ⫾ 23*
148.4 ⫾ 16.4*
115.0 ⫾ 17.8

Data were normalized to ␤-actin levels; values are percentage control ⫾ SD (n ⫽ 3).
*p ⬍ 0.05, each endpoint versus control (Dunnett’s many-to-one t test).

a

Results

onstrate that both MMP-2 and MMP-9 are expressed in isolated
brain capillaries from healthy rats.

MMP expression and activity in isolated rat brain capillaries
First, we isolated rat brain capillaries and analyzed protein expression and functional activity of MMP-2 and MMP-9 at the
blood-brain barrier. Figure 1A shows MMP-2 and MMP-9 immunostaining in freshly isolated rat brain capillaries. MMP-2 was
mainly localized at the abluminal membrane of rat brain capillaries (Fig. 1A, left, arrow), whereas MMP-9 was mainly localized
at the luminal membrane (Fig. 1A, middle, arrow, right, negative
control [no primary antibody] is an overlay of the green, blue,
and transmitted light channels). Using Western blotting, we detected a band for MMP-2 at 72 kDa and a band for MMP-9 at 92
kDa in liver lysate, liver crude membrane fraction, brain lysate,
choroid plexus lysate, and brain capillary lysate (Fig. 1B). In kidney brush border membranes, we detected a strong band for
MMP-9, whereas no obvious band was visible for MMP-2. In
another series of Western blots, we compared the expression of
MMP-2 and MMP-9 in brain capillary lysate and brain capillary
membrane fraction (Fig. 1C). MMP-2 expression was enriched in
brain capillary membranes compared with capillary lysate, whereas
MMP-9 protein expression levels were higher in brain capillary lysate compared with capillary membranes.
To determine MMP functional activity in rat brain capillaries,
we used a fluorogenic MMP assay using the nonfluorescent MMP
substrate Mca-PLGL-Dpa-AR-NH2. This peptide has a fluorescent 7-methoxycoumarin (Mca) moiety that is connected by a
PLGL peptide sequence with a 2,4-dinitrophenyl (Dpa) moiety
that quenches Mca fluorescence. MMP-mediated cleavage of the
PLGL sequence between the glycine and leucine releases Mca from
the Dpa quencher resulting in fluorescence. Because the PLGL peptide is a substrate for multiple MMPs, including MMP-1, -2, -7, -8,
-9, -12, -13, -14, -15, and -16, this assay determines overall MMP
functional activity. Using this assay, we detected fluorescence
(21,357 ⫾ 1023 absolute fluorescence units [AFU]) representing
MMP activity in isolated brain capillaries from control rats (Fig.
1D). Adding the broad-spectrum MMP inhibitor GM6001 reduced fluorescence significantly by 61% (8324 ⫾ 105 AFU; t(2) ⫽
10.37, p ⫽ 0.0092; unpaired t test; n ⫽ 3 independent experiments), indicating that MMPs are responsible for the largest
portion of the observed fluorescence. Together, these data dem-

Epileptic seizures mediate barrier leakage
Next, we tested the effect seizures have on blood-brain barrier integrity. We isolated brain capillaries from rats 48 h after pilocarpineinduced SE and analyzed protein expression levels of tight junction
proteins as well as MMP-2 and MMP-9 by Western blotting (Fig.
2A). MMP-2 and MMP-9 protein expression levels were increased in brain capillaries from animals that experienced SE. In
the same samples, protein expression levels of the tight junction
proteins ZO-1, occludin, claudin-1, and claudin-5 were decreased. Importantly, in brain capillaries from animals that received pilocarpine but did not experience SE, no such effects on tight
junction and MMP protein expression levels were observed, indicating that seizures, not pilocarpine, mediated the observed
changes in expression levels. Table 1 shows data from Western
blot analyses; the Dunnett’s test showed that for each endpoint SE
significantly ( p ⬍ 0.05) differed from controls.
TIMPs are endogenous inhibitors of MMPs and belong to the
family of protease inhibitors. We show that protein expression
levels of TIMP-1 and TIMP-2 are increased in isolated brain capillaries from SE animals, whereas TIMP-3 levels remained unchanged (Fig. 2B). Table 2 summarizes data from Western blot
analyses; the Dunnett’s test showed that TIMP-1 and TIMP-2
levels for SE are significantly ( p ⬍ 0.05) different from controls.
Consistent with increased MMP protein expression levels, gelatin
zymography showed increased MMP-9 activity (92 kDa) in brain
capillaries from SE rats compared with control rats (Fig. 2C). We
also determined MMP activity in lysate from brain capillaries
isolated from rats after SE and observed an increase in fluorescence by 80% (t(2) ⫽ 78.6, p ⫽ 0.0002; ANOVA post hoc test; n ⫽
2 independent experiments) compared with brain capillary lysate
from control animals, indicating that overall MMP activity was
increased in SE rats (Fig. 2D). In brain capillary lysate from rats
that received pilocarpine and experienced a few seizures (⬍10)
but did not develop SE, fluorescence was elevated by ⬃20%
(t(2) ⫽ 19.0, p ⫽ 0.0028; ANOVA post hoc test) compared with
controls (Fig. 2D).
To determine whether seizures affect blood-brain barrier integrity in isolated brain capillaries from male Sprague Dawley rats
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Figure 3. Glutamate increases MMP-2 and MMP-9 levels, decreases tight junction protein levels, and causes barrier leakage in isolated brain capillaries. A, Western blot showing MMP-2, MMP-9,
ZO-1, occludin, claudin-1, and claudin-5 in isolated rat brain capillaries exposed to 0, 50, or 100 M glutamate (Glu); ␤-actin was used as protein loading control. B, Western blot showing TIMP-1,
TIMP-2, and TIMP-3 protein expression in isolated brain capillaries from control, pilocarpine, and SE rats. C, MMP-2 protein levels in rat brain capillary lysate determined by ELISA from control
capillaries and capillaries exposed to 100 M glutamate. Data are mean ⫾ SEM (n ⫽ 3 independent experiments; pooled tissue of n ⫽ 10 rats per experiment). Statistical comparison: **t(4) ⫽ 6.65,
p ⫽ 0.0027 (unpaired t test). D, MMP-9 protein levels in rat brain capillary lysate determined by ELISA from control capillaries and capillaries exposed to 100 M glutamate. Data are mean ⫾ SEM
(n ⫽ 3 independent experiments; pooled tissue of n ⫽ 10 rats per experiment). Statistical comparison: **t(4) ⫽ 4.63, p ⫽ 0.0098 (unpaired t test). E, Texas Red leakage from rat brain capillaries
exposed to 100 M glutamate; high osmotic mannitol was used as positive control for barrier opening. Data are 0 –255 AFU and presented as mean ⫾ SEM for n ⫽ 7 brain capillaries per time point
from one brain capillary isolation with n ⫽ 10 rats.

after SE, we used a previously established dye leakage assay (Hartz
et al., 2004, 2012). In this assay, isolated brain capillaries are exposed
to fluorescent Texas Red (641 Da, 2 M). Because Texas Red is a
substrate for the efflux transporter Mrp, it is actively transported into
the capillary lumen, where it accumulates (Bauer et al., 2008). After
1 h, when luminal Texas Red fluorescence levels reached steady
state, the dye is removed and Texas Red leakage from capillary
lumens is monitored over time by live cell imaging using confocal
microscopy. Luminal Texas Red fluorescence is quantified with
image analysis software. First-order Texas Red leakage rate con-

Table 3. Western blot analysis of MMP and tight junction protein expression levels
in brain capillaries exposed to glutamate (Fig. 3A)a
Protein

Control

50 M glutamate

100 M glutamate

MMP-2
MMP-9
ZO-1
Occludin
Claudin-1
Claudin-5

100 ⫾ 11.2
100 ⫾ 2.0
100 ⫾ 6.4
100 ⫾ 0.9
100 ⫾ 2.3
100 ⫾ 15.6

91.1 ⫾ 9.7
102.4 ⫾ 2.1
92.8 ⫾ 6.4
102.8 ⫾ 1.0
100.5 ⫾ 5.2
92.4 ⫾ 17.1

191.2 ⫾ 8.4*
169.2 ⫾ 3.6*
42.3 ⫾ 3.3*
86.4 ⫾ 0.8*
59.8 ⫾ 2.5*
83.9 ⫾ 2.9*

Data were normalized to ␤-actin levels; values are percentage control ⫾ SD (n ⫽ 3).
*p ⬍ 0.05, each endpoint versus control (Dunnett’s many-to-one t test).

a
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stants were calculated by nonlinear regression (Prism, version 7.00; RRID:
SCR_002798, GraphPad). Using this
assay, we demonstrate that the Texas Red
leakage rate constant from brain capillary
lumens of SE rats (0.18 ⫾ 0.05 min ⫺1)
was 18-fold higher compared with the
Texas Red leakage rate constant from capillaries from control rats (0.01 ⫾ 0.03
min ⫺1, Fig. 2E). The leakage rate constant
from capillaries of SE rats was sixfold
higher than in capillaries from rats that
received pilocarpine and had some seizures but did not experience SE (0.03 ⫾
0.02 min ⫺1; Fig. 2E). The Texas Red leakage rate constant from brain capillaries of
SE rats (0.18 ⫾ 0.05 min ⫺1) was comparable with that from brain capillaries exposed to a hypertonic (100 mM) mannitol
solution (0.14 ⫾ 0.03 min ⫺1), which was
used as a positive control to osmotically
open the barrier and increase Texas Red
leakage (i.e., increase capillary permeability)
(Hartz et al., 2004, 2012). Further, in serum
isolated from SE rats, we found significantly
elevated levels of S100␤, an astrocytic protein that is used as a marker for barrier leakage, compared with control animals (Fig.
2F; Control vs SE: t(2) ⫽ 3.79, p ⬍ 0.0012;
Pilo vs SE: t(2) ⫽ 3.58, p ⬍ 0.002; ANOVA
post hoc tests; n ⫽ 2 independent
experiments).
Together, these data suggest that
seizure-induced increases in MMP-2 and
MMP-9 expression and activity levels result in decreased expression levels of tight
junction proteins and blood-brain barrier
leakage.
Glutamate triggers barrier leakage
Glutamate is the most important excitatory neurotransmitter in the brain that is
released in excessive amounts during seizures and has been shown to change
blood-brain barrier properties (Ueda and
Tsuru, 1995; Bauer et al., 2008; Pekcec et
al., 2009; Zibell et al., 2009; Hartz et al.,
2017). Here, we postulated that glutamate
triggers barrier leakage. To test this hy- Figure 4. Glutamate increases MMP activity in isolated brain capillaries. A, Representative MMP-9 gelatin zymogram of lysate
pothesis, we used a protocol we previously from brain capillaries exposed to 100 M glutamate. Left, Recombinant MMP-9 (positive control). B, Densitometric analysis of n ⫽
established (Bauer et al., 2008) and ex- 4 gelatin zymograms. Data are mean ⫾ SEM (n ⫽ 4 independent experiments) and show the fold change over controls (1.81 ⫾
posed isolated rat brain capillaries to 50 0.28-fold; t(6) ⫽ 5.77, p ⫽ 0.0012; unpaired t test) for MMP-9 activity in lysate from rat brain capillaries exposed to 100 M
and 100 M glutamate, removed gluta- glutamate. C, Total MMP enzyme activity in brain capillaries was measured using the fluorogenic substrate Mca-PLGL-Dpa-ARmate after 30 min, and incubated capil- NH2. MMP activity was measured in lysate from isolated brain capillaries exposed to 100 M glutamate; recombinant rat MMP-2
laries in glutamate-free buffer for and rat MMP-9 were used as positive controls. MMP activity is given as AFU; data are mean ⫾ SEM (n ⫽ 3 independent experiadditional 5.5 h. After a total incubation ments). *Significantly lower than control (t(4) ⫽ 3.44, p ⫽ 0.026, unpaired t test). **Significantly higher than control, p ⬍ 0.01.
time of 6 h, brain capillaries were anaprotein levels in brain capillaries. In contrast, 50 M glutamate
lyzed. Similar to the effects observed in SE rats, we found dehad
little to no effect on the expression levels of both tight junccreased expression levels of the tight junction proteins ZO-1,
tion proteins and MMPs. Table 3 summarizes data from Western
occludin, and claudin-1 by Western blotting in isolated memblot analyses; the Dunnett’s test showed that for each endpoint
branes of brain capillaries exposed to 100 M glutamate; the effect
treatment with 100 M glutamate, protein expression levels of
of glutamate on claudin-5 expression levels was minimal (Fig.
MMP-2, MMP-9, ZO-1, occludin, and claudins-1 and -5 were
3A). Moreover, 100 M glutamate increased MMP-2 and MMP-9
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Figure 5. Effect of inhibiting MMPs on glutamate-mediated barrier leakage. A, Total MMP enzyme activity in brain capillaries was assessed by using the fluorogenic substrate Mca-PLGL-DpaAR-NH2. MMP activity was measured in lysate from isolated brain capillaries exposed to 100 M glutamate with or without the MMP inhibitor GM6001. MMP activity is given as AFU; data are mean ⫾
SEM (n ⫽ 3 independent experiments; pooled tissue of 10 rats per experiment). Statistical comparison: *control: 10.7 ⫾ 0.6 AFU; glutamate: 16.8 ⫾ 0.8 AFU; glutamate ⫹ GM6001: 11.3 ⫾ 0.2
AFU; glutamate ⫹ GM6001 versus control: t(2) ⫽ 0.69, p ⫽ 0.56; glutamate ⫹ GM6001 versus glutamate: t(2) ⫽ 4.83, p ⫽ 0.04 (ANOVA post hoc tests). B, Texas Red leakage was measured in
capillaries exposed to 100 M glutamate with or without the MMP inhibitor GM6001.

significantly ( p ⬍ 0.05) different from controls. In contrast to
MMPs, protein expression levels of TIMP-1, TIMP-2, and
TIMP-3 remained unchanged in capillaries exposed to glutamate
(Fig. 3B). This suggests that TIMPs may be regulated via a different pathway that does not involve glutamate signaling. To further
quantitate the glutamate-mediated increase of MMP protein expression levels, we also determined MMP-2 and MMP-9 protein
levels by ELISA. Figure 3C shows that MMP-2 protein levels in
brain capillaries exposed to glutamate increased by 45% compared
with control capillaries (control: 0.105 ⫾ 0.005 ng/ml, glutamate:
0.152 ⫾ 0.005 ng/ml; n ⫽ 3 independent experiments, t(4) ⫽ 6.65,
p ⫽ 0.0027; unpaired t test). Figure 3D shows that MMP-9 protein
levels increased by 115% (control: 0.202 ⫾ 0.04 ng/ml, glutamate:
0.434 ⫾ 0.03 ng/ml; n ⫽ 3 independent experiments, t(4) ⫽ 4.63, p ⫽
0.0098; unpaired t test). Further, we determined Texas Red leakage
and found that brain capillaries exposed to glutamate had an increased Texas Red leakage rate constant compared with untreated
control capillaries (Fig. 3E). Texas Red leakage rate constants were
0.1 ⫾ 0.04 min ⫺1 for untreated control capillaries, 0.2 ⫾ 0.02 min ⫺1
for capillaries exposed to glutamate, and 0.3 ⫾ 0.08 min ⫺1 for capillaries exposed to high osmotic mannitol (positive control for barrier opening). Thus, exposing brain capillaries to glutamate
increased Texas Red leakage constant rates by twofold compared
with Texas Red leakage constant rates from untreated control capillaries. Together, these findings demonstrate that glutamate mediates
similar effects on tight junction and MMP protein expression levels
and capillary permeability in isolated brain capillaries to those effects
observed in brain capillaries isolated from SE rats. This suggests that
the effects seizures have on brain capillaries are mediated by glutamate that is released during seizures.
Glutamate increases MMP activity
We determined MMP activity in brain capillaries exposed to glutamate using gelatin zymography and the MMP activity assay described above. Figure 4A shows a representative zymogram with
strong bands at 92 kDa representing MMP-9. The zymogram

shows that exposing isolated rat brain capillaries to glutamate
increased MMP-9 activity compared with untreated control capillaries. MMP-9 standard protein (positive control) is shown in
the left lane. Figure 4B shows the results from optical density
measurements of zymograms from four independent experiments. These data demonstrate that glutamate increased MMP-9
activity (1.81 ⫾ 0.28-fold, t(6) ⫽ 5.77, p ⫽ 0.0012; unpaired t test)
compared with untreated control capillaries. For MMP-2 we observed faint bands in the zymogram (data not shown). When we
determined MMP activity, we found that exposing brain capillaries to glutamate significantly ( p ⬍ 0.05) increased total MMP
activity levels by 38% compared with control capillaries (control:
18,107 ⫾ 616 AFU, glutamate: 25,041 ⫾ 1917 AFU; n ⫽ 3 independent experiments; t(4) ⫽ 3.44, p ⫽ 0.026, unpaired t test; Fig.
4C). Recombinant MMP-2 and MMP-9 (6.25 ng each) were used
as standard controls (MMP-2: 20,944 ⫾ 1220 AFU; MMP-9:
16,509 ⫾ 538 AFU). Thus, the results from these experiments
demonstrate that exposing isolated rat brain capillaries to glutamate increases MMP activity.
MMP inhibition prevents glutamate-mediated blood-brain
barrier leakage
To further clarify the role of MMPs in glutamate-mediated barrier leakage, we exposed isolated rat brain capillaries to glutamate
with or without the broad-spectrum MMP inhibitor GM6001.
We found that glutamate-mediated increase in MMP activity was
fully blocked by GM6001 (control: 10.7 ⫾ 0.6 AFU; glutamate:
16.8 ⫾ 0.8 AFU; glutamate ⫹ GM6001: 11.3 ⫾ 0.2 AFU; glutamate ⫹ GM6001 vs control: t(2) ⫽ 0.69, p ⫽ 0.56; glutamate ⫹
GM6001 vs glutamate: t(2) ⫽ 4.83, p ⫽ 0.04, ANOVA post hoc
tests; n ⫽ 3 independent experiments; Figure 5A). Importantly,
GM6001 also fully blocked glutamate-mediated brain capillary
leakage as determined by the Texas Red assay (Fig. 5B). Thus,
GM6001 prevented barrier leakage, suggesting that MMP inhibition can maintain barrier function. These data indicate that
MMPs are involved in glutamate-mediated barrier leakage.
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Figure 6. Effect of inhibiting cPLA2 on glutamate-mediated MMP-2 and MMP-9 induction and barrier leakage. A, Western blots showing MMP-2 and MMP-9 protein expression in isolated rat
brain capillaries exposed to 100 M glutamate with or without the NMDAR antagonist MK801. ␤-Actin was used as protein loading control. B, Texas Red leakage assay showing glutamate-mediated
barrier leakage with or without the NMDAR antagonist MK801. C, Western blots showing MMP-2 and MMP-9 protein expression levels in isolated rat brain capillaries exposed to 100 M glutamate
with or without the cPLA2 inhibitor ATK. ␤-Actin was used as protein loading control. D, MMP activity assessed in isolated capillaries exposed to 100 M glutamate with or without ATK (ATK vs
control: t(2) ⫽ 3.08, p ⫽ 0.091; ANOVA post hoc test). E, Texas Red leakage assay showing glutamate-mediated barrier leakage with or without ATK (cPLA2 inhibitor). Texas Red leakage assay in
capillaries from (F ) wild-type and (G) cPLA2 KO mice that were exposed to 100 M glutamate with or without the cPLA2 inhibitor ATK. Data are 0 –255 AFU and presented as mean ⫾ SEM for n ⫽
7 brain capillaries per time point from one capillary isolation with n ⫽ 10 rats or n ⫽ 30 mice, respectively. ***Significantly higher than control, p ⬍ 0.001.
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Table 4. Western blot analysis of MMP protein expression levels in brain capillaries
exposed to glutamate (Fig. 6A)a
Protein

Control

100 M glutamate

⫹ MK801

MMP-2
MMP-9

100 ⫾ 8.2
100 ⫾ 4.2

190.8 ⫾ 6.1*
183.4 ⫾ 5.3*

129.8 ⫾ 6.6
123.0 ⫾ 5.8

Data were normalized to ␤-actin levels; values are percentage control ⫾ SD (n ⫽ 3).
*p ⬍ 0.05, each endpoint versus control (Dunnett’s many-to-one t test).

a

Table 5. Western blot analysis of MMP protein expression levels in brain capillaries
exposed to glutamate (Fig. 6C)a
Protein

Control

100 M glutamate

⫹ ATK

MMP-2
MMP-9

100 ⫾ 3.3
100 ⫾ 2.8

174.4 ⫾ 8.0*
174.1 ⫾ 3.2*

109.5 ⫾ 5.2
108.3 ⫾ 2.6

Data were normalized to ␤-actin levels; values are percentage control ⫾ SD (n ⫽ 3).
*p ⬍ 0.05, each endpoint versus control (Dunnett’s many-to-one t test).

a

Glutamate mediates barrier leakage by signaling
through cPLA2
In the following experiments, we identified signaling steps underlying glutamate-mediated MMP upregulation and barrier leakage. We
and other groups have previously shown that the NMDAR is expressed in brain capillaries and that glutamate signals through
NMDAR, which triggers changes at the blood-brain barrier (Zhu
and Liu, 2004; Bankstahl et al., 2008; Bauer et al., 2008). In the present study, we exposed isolated rat brain capillaries to glutamate with
or without the NMDAR antagonist MK801. Blocking the NMDAR
with MK801 abolished the glutamate-mediated increase in MMP-2
and MMP-9 protein expression levels as demonstrated by Western
blotting (Fig. 6A; for Western blot analyses, see Table 4). MK801 also
prevented the glutamate-mediated increase in the Texas Red leakage
rate constant (Fig. 6B; control: 0.2 ⫾ 0.09 min ⫺1; glutamate: 0.6 ⫾ 0.13
min ⫺1; glutamate and MK801: 0.2 ⫾ 0.08 min ⫺1; mannitol (positive
control): 0.7 ⫾ 0.17 min ⫺1). These data suggest that glutamate causes
barrier leakage by signaling through the NMDAR.
In the next set of experiments, we exposed isolated rat brain
capillaries to glutamate with or without ATK, a selective inhibitor
of cPLA2. ATK blocked the glutamate-mediated increase in
MMP-2 and MMP-9 protein expression levels as demonstrated
by Western blotting (Fig. 6C; for Western blot analyses, see Table
5). Inhibiting cPLA2 with ATK also prevented the glutamatemediated increase in MMP activity levels (Fig. 6D; ATK vs control: t(2) ⫽ 3.08, p ⫽ 0.091; ANOVA post hoc test). Consistent with
this, ATK attenuated the glutamate-mediated increase in Texas
Red leakage (Fig. 6E; control: 0.1 ⫾ 0.01 min ⫺1; glutamate: 0.4 ⫾
0.05 min ⫺1; glutamate and ATK: 0.2 ⫾ 0.04 min ⫺1; mannitol
[positive control]: 0.5 ⫾ 0.04 min ⫺1). Thus, inhibiting cPLA2
blocked the glutamate-mediated increase in MMP protein and
activity levels, thereby preventing capillary leakage. We repeated
this experiment with capillaries isolated from wild-type and
cPLA2 KO mice. As before, we observed leakage in capillaries
isolated from wild-type mice that were exposed to glutamate (Fig.
6F ); this effect was abolished by cPLA2 inhibition with ATK. In
contrast, exposing isolated brain capillaries from cPLA2 KO mice
to glutamate did not result in detectable Texas Red leakage compared with control capillaries (Fig. 6G). This indicates that glutamate triggers capillary leakage by signaling through cPLA2.
Together, these data show that inhibiting cPLA2 or genetically
knocking out cPLA2 abolishes glutamate-induced barrier leakage,
which, in turn, suggests that cPLA2 is responsible for glutamatemediated upregulation of MMPs and capillary leakage.

Inhibiting cPLA2 in vivo prevents SE-induced barrier leakage
To confirm that cPLA2 signaling is involved in SE-induced barrier leakage, we conducted an in vivo study using the specific
cPLA2 inhibitor ATK. Rats were dosed with ATK (10 mg/kg, i.p.)
every 12 h for 3.5 d (total of 7 i.p. injections); control rats received
vehicle injections. After 4 ATK treatments, rats underwent seizure induction with pilocarpine; after SE induction animals received 3 more treatments with ATK. Forty-eight hours after SE
induction, brain capillaries were isolated from control rats (n ⫽
6), pilocarpine control rats (n ⫽ 4), SE rats (n ⫽ 6), and ATKtreated SE rats (n ⫽ 6). As before, we detected increased MMP-2
and MMP-9 protein expression levels and decreased tight junction protein expression levels in brain capillaries isolated from
rats after SE (Fig. 7A; for Western blot analyses, see Table 6).
However, in animals treated with ATK, MMP and tight junction
protein levels were comparable with those in capillaries from
control animals and animals that received pilocarpine but did not
develop SE. Data from analyzed Western blots (Table 2) show
that MMP-2, MMP-9, and claudin-5 protein expression levels in
brain capillaries from SE animals were significantly different (p ⬍ 0.05;
Dunnett’s test) from those of the control group. Only MMP-2
protein expression levels in brain capillaries from ATK-treated
SE rats differed from control rats. Protein expression levels in
brain capillaries from rats that received pilocarpine but did not
experience SE did not differ from protein levels in capillaries
from control rats for any of the endpoints. Consistent with this,
ATK also blocked SE-mediated capillary leakage as measured by
the Texas Red leakage assay (control: 0.03 ⫾ 0.02 min ⫺1; pilocarpine: 0.03 ⫾ 0.05 min ⫺1; SE: 0.10 ⫾ 0.02 min ⫺1; SE ⫹ ATK:
0.03 ⫾ 0.01 min ⫺1; mannitol [positive control]: 0.21 ⫾ 0.04
min ⫺1, Fig. 7B). Thus, dosing rats with ATK to inhibit cPLA2
blocks the SE-mediated increase in MMP protein levels, the decrease
in tight junction protein levels, and prevents barrier leakage.
Together, our observations indicate that cPLA2 inhibition in vivo
prevents seizure-induced upregulation of MMP2 and MMP-9, decreased TJ protein levels and barrier leakage in rats that experienced SE. Thus, cPLA2 appears to be involved in mediating
seizure-induced barrier dysfunction.

Discussion
In the present study, we show that MMP-2 and MMP-9 are expressed and functionally active in isolated rat brain capillaries
(Fig. 1). We also demonstrate that seizures result in increased
MMP-2 and MMP-9 protein and activity levels, reduced expression
levels of the tight junction proteins ZO-1, occludin, claudin-1, and
claudin-5, elevated S100␤ serum levels, and in capillary leakage
(Fig. 2). We found increased expression levels of TIMP-1 in capillaries isolated from rats that experienced seizures (Fig. 2B),
which is similar to the finding that TIMP-1 is upregulated in
neurons and astrocytes in rats after kainic acid-induced seizures
(Rivera et al., 1997). However, TIMP-1, TIMP-2, and TIMP-3
protein expression levels did not change in capillaries exposed to
glutamate, suggesting that TIMPs may be regulated via a different
pathway that does not involve glutamate signaling (Fig. 3B). We
further demonstrate that glutamate signals through the NMDAR,
which triggers increases in MMP expression and capillary leakage
(Figs 6 A, B). We also show that glutamate signals through cPLA2
to trigger increases in MMP expression and activity levels, decreases in tight junction protein levels, and capillary leakage ex
vivo (Figs. 3–6). We confirmed these findings in vivo by using the
potent and selective cPLA2 inhibitor ATK in a rat seizure model.
We show that ATK treatment blocks seizure-induced increases in
MMP expression levels, decreases in tight junction protein levels,
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Figure 7. Inhibition of cPLA2 in vivo in SE rats. A, Western blot showing MMP-2, MMP-9, ZO-1, occludin, claudin-1, and claudin-5 in brain capillaries isolated from control rats (Ctrl) and from rats
that experienced pilocarpine-induced SE, that received pilocarpine but did not develop SE (Pilo), and that experienced SE and received the cPLA2 inhibitor ATK (SE ⫹ ATK). B, Texas Red leakage in
brain capillaries from control rats (n ⫽ 6), pilocarpine control rats (n ⫽ 4), SE control rats (n ⫽ 6), and ATK-treated SE rats (n ⫽ 6). High osmotic mannitol was used as positive marker for capillary
leakage. Data are 0 –255 AFU and are presented as mean ⫾ SEM for n ⫽ 7 brain capillaries per time point from pooled tissue per group.
Table 6. Western blot analysis of MMP and tight junction protein expression levels
in brain capillaries isolated from rats after SE that were treated with or without
the cPLA2 inhibitor ATK (Fig. 7A)a
Protein

Control

Pilo

SE

SE ⫹ ATK

MMP-2
MMP-9
ZO-1
Occludin
Claudin-1
Claudin-5

100 ⫾ 2.9
100 ⫾ 3.9
100 ⫾ 11.6
100 ⫾ 16.9
100 ⫾ 15.3
100 ⫾ 15.6

102.6 ⫾ 2.9
106.2 ⫾ 3.5
115.7 ⫾ 16.4
96.1 ⫾ 19.1
95.3 ⫾ 16.6
92.4 ⫾ 17.1

145.2 ⫾ 3.4*
139.6 ⫾ 9.2*
53.4 ⫾ 8.4*
41.2 ⫾ 5*
49 ⫾ 3.7*
44.9 ⫾ 3.8*

111.3 ⫾ 2.8
99.2 ⫾ 4.3
101.8 ⫾ 15.7
89 ⫾ 23.6
105.5 ⫾ 18.4
110.7 ⫾ 19

Data were normalized to ␤-actin levels; values are percentage control ⫾ SD (n ⫽ 3).
*p ⬍ 0.05, each endpoint versus control (Dunnett’s many-to-one t test).

a

and prevents capillary leakage (Fig. 7). Based on these data, we
propose that seizure-induced release of glutamate leads to activation of cPLA2, which, in turn, increases MMP expression and
activity levels. MMPs then decrease tight junction protein expression resulting in barrier leakage (Fig. 8). Together, our data suggest that cPLA2 could be a potential pharmaceutical target to
normalize barrier function and improve treatment of epilepsy. In
the following sections, we discuss several points of the present
study in more detail.
Recent studies have shown that the blood-brain barrier is severely altered in epilepsy and that barrier dysfunction affects neuronal function and leads to seizures (Marchi et al., 2007a,b; Rigau
et al., 2007; van Vliet et al., 2007; Tomkins et al., 2008; Kastanauskaite et al., 2009; Alonso-Nanclares and DeFelipe, 2014).
One critical element of barrier dysfunction is barrier leakage,

which was observed in animal seizure and epilepsy models as well
as in epilepsy patients (Nitsch and Klatzo, 1983; Mihály and
Bozóky, 1984; Cornford and Oldendorf, 1986; Horowitz et al.,
1992; Padou et al., 1995). Our data from the present study are
consistent with these observations. Several studies showed that
blood-brain barrier leakage in epilepsy was restricted to anatomically specific brain regions and that these brain regions are often
implicated in the development and propagation of seizures (Nitsch
and Klatzo, 1983; Cornford et al., 1998). This suggests a connection
between barrier leakage and seizures. Indeed, recent studies provide additional evidence for the hypothesis that a leaky barrier
contributes to seizure genesis through a pernicious feedback
loop, in which seizures drive barrier leakage, leading to more
seizures, thereby promoting epilepsy progression (Seiffert et al.,
2004; Marchi et al., 2007b, 2010, 2011; van Vliet et al., 2007;
Fabene et al., 2008).
The exact mechanism by which barrier leakage develops in
epilepsy is unknown. Rapid increases in vascular permeability
following seizures have been reported by Uva et al. (2008) and
Vazana et al. (2016). In the present study, we focus on seizureinduced effects on barrier function that are mediated MMPs. The
extracellular matrix together with tight junction proteins seal the
endothelial cells and thus are critical components for proper barrier function. Previously, it has been shown that MMPs cleave the
extracellular matrix and degrade tight junction proteins, thereby
contributing to barrier leakage (Lischper et al., 2010; Thanabalasundaram et al., 2010). Based on these data, we hypothesized
that MMPs may be key players responsible for barrier leakage in
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Figure 8. Proposed signaling pathway.

epilepsy. In this regard, we show that MMP-2 and MMP-9 are
expressed in different rat tissues, including isolated brain capillaries. These data are consistent with previous reports (Zeisberg et al.,
2002; Nico et al., 2006; Zeni et al., 2007; Thanabalasundaram et al.,
2010; Hartz et al., 2012; Kurzepa et al., 2014). To test whether
MMPs are functionally active in isolated brain capillaries, we
used gelatin zymography. Although we detected strong bands for
MMP-9 activity, band intensity for MMP-2 activity was low and
could not be clearly visualized. We therefore developed an MMP
assay based on the digestion of the fluorogenic MMP substrate
PLGL. Because PLGL is a substrate for various MMPs, the data
obtained from this assay reflect overall MMP activity in brain
capillary samples. The only MMPs known to be expressed in the
brain capillary endothelium are MMP-2, MMP-9, and MMP-14
(or MT1-MMP; which is known to activate MMP-2). Based on
preliminary data (data not shown) from our group, MMP-14
protein is expressed at relatively low levels compared with MMP-2
and MMP-9. Therefore, we conclude that the assay we used here
mainly determines MMP-2 and MMP-9 activity in isolated brain
capillaries. Based on our preliminary data with brain lysate (data not
shown), we found no increase in MMP activity in brain tissue
from SE animals compared with control animals. This indicates
that the observed increase of MMP activity after seizures appears
to be specific to brain capillaries.
The data from rats that experienced an SE also suggest that
seizures lead to increased MMP levels, which in turn leads to
decreased tight junction protein levels, thereby causing barrier
leakage within 48 h after SE. This is consistent with findings from
human studies showing increased blood-brain barrier permeability
shortly after seizure onset (Clarke and Gabrielsen, 1989; Marchi et
al., 2007a; Rigau et al., 2007; van Vliet et al., 2007; Tomkins et al.,
2008). Preclinical studies with patients evaluated for acute stroke
suggest a significant relationship between MMP-9 and barrier
leakage in humans (Barr et al., 2010). Utilizing a mouse model of
cortical spreading depression, Gursoy-Ozdemir et al. (2004)
showed that increased MMP-9 activity causes barrier leakage,
which was confirmed in MMP-9 KO mice. Le and Friedman
(2012) recently reported that proMMP-7 protein levels were elevated in culture medium from brain slices exposed to kainic acid
for 24 h. They also observed that MMP-7 protein and activity
levels were decreased and TIMP-1 protein expression levels were
increased in hippocampal sections after kainic acid-induced seizures. In contrast, we found that MMP-2 and MMP-9 as well as
TIMP-1 and TIMP-2 were elevated in isolated brain capillaries
48 h after SE induction with pilocarpine (Fig. 2), suggesting that
the observed increase in TIMP levels was not sufficient to block
MMP activity in capillaries. Le and Friedman (2012) also demonstrated that exogenously supplied MMP-7 to hippocampal slices in
combination with kainic acid displayed a neuroprotective effect,
which highlights the ambivalent role MMPs play in epilepsy.
A critical discovery was made in 1975 when Nemeroff and
Crisley (1975) found that intraperitoneal injections of monosodium L-glutamate (4.0 g/kg) induce seizures in rats and lead to
increased blood-brain barrier permeability to plasma proteins. In
1995, Ueda and Tsuru (1995) reported that glutamate is excessively released during seizures; this finding was confirmed by
other groups (Ronne-Engström et al., 1992; During and Spencer,

1993; Wilson et al., 1996). We previously reported that glutamate
released by seizures acts as an initial trigger of a signaling cascade
in brain capillary endothelial cells that drives upregulation of the
drug efflux transporter P-glycoprotein. In this regard, we demonstrated that glutamate signaling is mediated through the NMDAR,
cyclooxygenase (COX)-2, and the prostaglandin E2 receptor EP1
(Bauer et al., 2008; Pekcec et al., 2009; Zibell et al., 2009). Here, we
demonstrate in brain capillaries that glutamate also acts as an
initial trigger of a signaling cascade that results in elevated
MMP-2 and MMP-9 protein and activity levels, decreased expression levels of the TJ proteins occludin, claudin-1, claudin-5
and ZO-1, and consequently barrier leakage. Together, these data
confirm our previously published reports and provide additional
and novel insights into the underlying mechanism through which
glutamate triggers barrier leakage.
The neurotransmitter glutamate exerts its effects by activating
glutamate receptors. We and others previously showed that the
glutamate receptor NMDAR is expressed in brain capillary endothelial cells (Bauer et al., 2008; Betzen et al., 2009) and that it
mediates seizure- and glutamate-induced increases in P-gp protein expression and transport activity levels (Zhu and Liu, 2004;
Bankstahl et al., 2008; Bauer et al., 2008). We show that the NMDAR is
also involved in glutamate-induced increases in MMP-2 and MMP-9
protein expression levels and in glutamate-induced brain capillary
leakage (Fig. 6 A, B). This is consistent with a previous report showing that NMDAR is critical for glutamate-induced decreases of occludin protein expression levels leading to decreased endothelial
integrity in brain microvascular endothelial cells (András et al.,
2007). Vazana et al. (2016) found that seizure-induced glutamate
release in rats leads to vascular permeability through activation of the
NMDAR. Betzen et al. (2009) demonstrated in cell culture experiments in vitro that oxidative stress upregulates NMDAR protein expression and activity levels, which leads to glutamate-induced
barrier leakage in the mouse brain capillary bEND3 cell line. In contrast, Sharp et al. (2005) showed that human cerebral endothelial
cells respond to glutamate by generating oxidative stress via activation of the NMDAR. Together, these data suggest a key role for the
NMDAR in glutamate-mediated barrier dysfunction.
Glutamate has also been shown to activate calcium-dependent
cPLA2 to trigger downstream signaling events (Six and Dennis, 2000;
Shen et al., 2007; Shelat et al., 2008). Here we demonstrate that
cPLA2 inhibition fully abolished all observed glutamate effects
and thus prevented the increase in MMP expression and activity
levels, the decrease in tight junction protein levels, and capillary
leakage. Further, we show that the cPLA2 inhibitor ATK prevents
seizure-induced barrier leakage and normalizes MMP levels as
well as ZO-1, occludin, claudin-1, and claudin-5 protein levels.
Based on these findings, we conclude that seizure-induced glutamate release results in cPLA2 activation, which leads to barrier
leakage. Our data imply that arachidonic acid, a second messenger and key inflammatory intermediate generated by cPLA2, is
involved in this signaling pathway. After its release, arachidonic
acid is converted by cyclooxygenase-2 into prostaglandins or by
5-lipoxygenase into leukotrienes (Samuelsson et al., 1978; Goetzl
et al., 1980; Sirois et al., 1980).
Together, our data suggest that cPLA2 inhibition has the potential to prevent blood-brain barrier leakage and that cPLA2
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could be an additional therapeutic target in the treatment of epilepsy and help reduce seizure burden. However, this needs further confirmation and should be considered carefully. Because
cPLA2 signaling is a component of the brain’s inflammatory response, targeting cPLA2 could have a range of consequences, expected and beneficial as well as unintended and detrimental. For
example, given that cPLA2 is part of the COX-2 pathway, inhibiting cPLA2 is likely to cause side effects similar to those observed
for NSAIDs. Further, whereas the majority of studies using COX-2
inhibitors showed a neuroprotective effect in animal seizure and
epilepsy models, some studies showed that COX-2 inhibition
resulted in an increased seizure burden, neuronal loss, and death
(Baik et al., 1999; Desjardins et al., 2003; Takemiya et al., 2006;
Holtman et al., 2010; Polascheck et al., 2010).
In conclusion, in the present study, we use a combined ex
vivo/in vivo approach and demonstrate at the blood-brain barrier
that seizures increase MMP-2 and MMP-9 levels, resulting in
reduced levels of tight junction proteins and subsequently barrier
leakage. We also show that glutamate signals through cPLA2 to
trigger these changes ex vivo and in vivo. Thus, we propose cPLA2
as a potential pharmaceutical target to repair barrier dysfunction
and improve epilepsy treatment. Additional studies are needed to
gain more detailed insight into the mechanism responsible for
barrier leakage in epilepsy and to test whether cPLA2 has potential as a therapeutic target for epilepsy treatment and other neurological disorders with underlying barrier dysfunction.

References
Alonso-Nanclares L, DeFelipe J (2014) Alterations of the microvascular network in the sclerotic hippocampus of patients with temporal lobe epilepsy. Epilepsy Behav 38:48 –52. CrossRef Medline
András IE, Deli MA, Veszelka S, Hayashi K, Hennig B, Toborek M (2007)
The NMDA and AMPA/KA receptors are involved in glutamate-induced
alterations of occludin expression and phosphorylation in brain endothelial cells. J Cereb Blood Flow Metab 27:1431–1443. CrossRef Medline
Baik EJ, Kim EJ, Lee SH, Moon C (1999) Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the
hippocampus. Brain Res 843:118 –129. CrossRef Medline
Bankstahl JP, Hoffmann K, Bethmann K, Löscher W (2008) Glutamate is
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